Citizens raised the firm's price target on Avalo Therapeutics to $62 from $52 and keeps an Outperform rating on the shares. Avalo Therapeutics reported positive Phase 2 results for abdakibart in hidradenitis suppurativa, demonstrating competitive efficacy and a favorable safety profile, supporting blockbuster potential and strengthening confidence in its clinical and commercial outlook, the analyst tells investors in a research note.
